---
schema_version: "secwatch.filing_event.v1"
accession: "0001729149-26-000028"
form_type: "8-K"
ticker: "VMD"
cik: "0001729149"
company_name: "VIEMED HEALTHCARE, INC."
filed_at: "2026-05-05T23:59:59+00:00"
generated_at: "2026-05-14T23:28:01.983543+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Viemed Healthcare reports Q1 2026 revenue of $75.4M, raises full-year guidance

## Summary
- Net revenues increased 28% to $75.4 million for Q1 2026, up from $59.1 million in Q1 2025.
- Adjusted EBITDA for Q1 2026 was $14.3 million, a 12% increase versus the prior year quarter.
- Company repurchased 150,000 common shares at an average price of $9.29 per share during Q1.
- Ventilator patient count reached 12,089; PAP therapy patient count grew 57% to 35,938 as of March 31.
- Full-year 2026 net revenue guidance raised to $312–$320 million from prior $310–$320 million.

## SEC filing metadata
- accession: 0001729149-26-000028
- form_type: 8-K
- ticker: VMD
- cik: 0001729149
- company_name: VIEMED HEALTHCARE, INC.
- filed_at: 2026-05-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1729149/000172914926000028/0001729149-26-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1729149/000172914926000028/vmd-20260505.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001729149-26-000028
- JSON: https://secwatch.observer/filing/0001729149-26-000028.json
- Plain text: https://secwatch.observer/filing/0001729149-26-000028.txt

## Source-grounded claims
- claim_id: 339a064886f70448d239c552b169cc2c70623d14
  claim: VIEMED HEALTHCARE, INC. reported the three months ended March 31, 2026 results: revenue $75.4 million, net income $2.6 million, EPS $0.06 per diluted share. Guidance raised.
  evidence_excerpt: and updated guidance for the full year ending December 31, 2026. Operational highlights (all dollar amounts are USD): • Net revenues for the quarter ended March 31, 2026 were $75.4 million, representing an increase of $16.3 million, or 28%, over net revenues reported for the comparable quarter ended March 31, 2025. • Net income attributable to Viemed for the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1729149/000172914926000028/0001729149-26-000028-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.